Skip to main content
SpringerLink
Log in

Abscopal-Effekt in der Therapie des malignen Melanoms

Abscopal effect in the treatment of malignant melanoma

  • Kasuistiken
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Unter dem Abscopal-Effekt versteht man die Reduktion von Metastasen außerhalb des Bestrahlungsareales nach lokaler Bestrahlung.

Fallbeschreibung

Der vorliegende Fall eines Patienten mit metastasiertem Melanom beschreibt die sequenzielle Gabe von Temozolomid und Ipilimumab plus Radiotherapie. Das applizierte Therapieschema wurde vom Patienten gut vertragen. Es konnte unter dieser Therapie eine ungewöhnlich lange Krankheitsstabilisierung bei Eradikation von zerebralen und renalen Metastasen erzielt werden. Ein Abscopal-Effekt kann vermutet werden.

Schlussfolgerung

Der hier zur Vorstellung gelangende Fall soll die Relevanz des Abscopal-Phänomens ins klinische Bewusstsein in der Therapie des malignen Melanoms rücken.

Abstract

Background

The clearance of non-irradiated tumors after localized radiation therapy is known as the abscopal effect.

Case report

In the present case report we initiated a combined therapeutic approach based on sequential administration of ipilimumab plus temozolomide in combination with radiotherapy. The treatment regime was well tolerated and resulted in unusually long disease stabilization and in a complete response of brain and kidney metastases. Thus, it is speculated that the clinical response was the result of an abscopal effect.

Conclusion

The present case report highlights the possible clinical benefit of the abscopal effect in the treatment of malignant melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Fonkem E, Uhlman EJ, Mahadevan A et al (2012) Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 12(10):1207–1215

    Article  CAS  PubMed  Google Scholar 

  2. Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11(9):1699–1707

    Article  CAS  PubMed  Google Scholar 

  3. Hodi FS, Oble DA, Drappatz J et al (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557–561

    Article  CAS  PubMed  Google Scholar 

  4. Di Giacomo AM Ascierto PA, Pilla L et al (2012) Ipilimumab and fotemustinein patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–886

    Article  CAS  PubMed  Google Scholar 

  5. Weber JS, Amin A, Minor D et al (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trail. Melanoma Res 21:530–534

    Article  CAS  PubMed  Google Scholar 

  6. Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059

    Article  CAS  PubMed  Google Scholar 

  8. Matsumura S, Wang B, Kawashima N et al (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181:3099–3107

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Demaria S, Pilones KA, Formenti SC et al (2013) Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA4 treatment. Oncoimmunology 2(3):e23127

    Article  PubMed Central  PubMed  Google Scholar 

  10. Dewan MZ, Galloway AE, Kawashima N et al (2009) Fractionated but not single-dose radiotherapy. Clin Cancer Res 1(15):5379–5388

    Article  Google Scholar 

  11. Iversen TZ, Klinge Brimnes M, Nikolajsen K et al (2013) Depletion of T lymphocytes is correlated with response to temazolamide in melanoma patients. Oncoimmunology 2(2):e23288

    Article  PubMed Central  PubMed  Google Scholar 

  12. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307

    Article  CAS  PubMed  Google Scholar 

  13. Scherill B, Wang J, Kotapati S et al (2013) Q-Twist analysis comparing ipilimumab/dacarbazine vs. placebo/dacarbazine for patient stage III/IV melanoma. Br J Cancer 109(1):8–13

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Onkologie, Comprehensive Cancer Center, Universitätsklinik für Innere Medizin I, AKH Wien, Medizinische Universität Wien, Währingergürtel 18–20, 1090, Wien, Österreich

    C. Thallinger MBA, MSc, G. Prager & C. Zielinski

  2. Universitätsklinik für Radiologie, Medizinische Universität Wien, Wien, Österreich

    H. Ringl

Authors
  1. C. Thallinger MBA, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Prager
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Ringl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Thallinger MBA, MSc.

Ethics declarations

Interessenkonflikt

C. Thallinger,G. Prager, H. Ringl und C. Zielinski geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thallinger, C., Prager, G., Ringl, H. et al. Abscopal-Effekt in der Therapie des malignen Melanoms. Hautarzt 66, 545–548 (2015). https://doi.org/10.1007/s00105-014-3567-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-014-3567-8

Schlüsselwörter

Keywords

Search

Navigation